Regulus Therapeutics Inc (NASDAQ:RGLS) CFO Daniel R. Chevallard sold 10,000 shares of the stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $1.41, for a total transaction of $14,100.00. Following the completion of the sale, the chief financial officer now directly owns 90,539 shares of the company’s stock, valued at $127,659.99. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Shares of NASDAQ:RGLS traded down $0.03 during trading on Friday, reaching $1.16. The stock had a trading volume of 477,811 shares, compared to its average volume of 257,980. Regulus Therapeutics Inc has a 52 week low of $0.80 and a 52 week high of $9.48. The firm has a market cap of $14.29 million, a price-to-earnings ratio of -0.21 and a beta of 2.26.
Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.84. Regulus Therapeutics had a negative net margin of 526.10% and a negative return on equity of 186,717.70%. The business had revenue of $6.78 million for the quarter, compared to the consensus estimate of $0.02 million. As a group, research analysts expect that Regulus Therapeutics Inc will post -2.39 EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in RGLS. Wedbush Securities Inc. raised its holdings in shares of Regulus Therapeutics by 32.8% in the first quarter. Wedbush Securities Inc. now owns 43,489 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 10,751 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Regulus Therapeutics in the first quarter valued at about $64,000. Virtu Financial LLC bought a new position in shares of Regulus Therapeutics in the first quarter valued at about $68,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Regulus Therapeutics by 396.3% in the third quarter. Renaissance Technologies LLC now owns 595,501 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 475,512 shares during the last quarter. 25.17% of the stock is owned by institutional investors and hedge funds.
A number of research firms have recently issued reports on RGLS. Wedbush reissued a “hold” rating and issued a $1.00 price target on shares of Regulus Therapeutics in a research report on Thursday. ValuEngine lowered shares of Regulus Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. Wells Fargo & Co reduced their price target on shares of Regulus Therapeutics from $6.00 to $1.50 and set a “market perform” rating for the company in a research report on Tuesday, March 19th. Finally, Zacks Investment Research raised shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a research report on Friday, March 29th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company. Regulus Therapeutics currently has a consensus rating of “Hold” and an average target price of $1.06.
ILLEGAL ACTIVITY WARNING: This news story was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.thelincolnianonline.com/2019/05/17/regulus-therapeutics-inc-rgls-cfo-sells-14100-00-in-stock.html.
About Regulus Therapeutics
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Further Reading: What are different types of coverage ratios?
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.